Optherion's Protein Replacement For AMD Nabs $37M Series A

Morrison, Trista
October 2007
BioWorld Today;10/10/2007, Vol. 18 Issue 197, p1
The article reports on the amount raised by New Haven, Connecticut-based Optherion Inc. from a Series A financing. The company raised $37 million to advance its preclinical research with a new approach to diagnosing and treating age-related macular degeneration (AMD). The company is pursuing the genetic link between AMD and mutations in the genes for Complement Factors H and B, as well as variations in Chromosome 10.


Related Articles

  • Optherion wins protection from Canada for AMD diagnostics.  // Diagnostics & Imaging Week;5/7/2009, Vol. 12 Issue 18, p3 

    The article announces that the Canadian Patent Office has granted Optherion patents 2,363,503 and 2,407,715. The patents offer protection for diagnostic tests to identify the predisposition to age-related macular degeneration (AMD) by screening for genetic modificaitons in various genes such as...

  • Sequenom acquires rights to Optherion's AMD genetic tests.  // Medical Device Daily;2/10/2010, Vol. 14 Issue 27, p3 

    The article reports on the exclusive worldwide licensing agreement reached by Sequenom with Optherion in February 2010. It states that the deal will allow the Sequenom Center for Molecular Medicine the rights to manufacture and market diagnostic tests to predict genetic predisposition to late...

  • Financings roundup.  // Medical Device Daily;10/10/2007, Vol. 11 Issue 194, p5 

    The article reports that Optherion, a company developing products to diagnose and treat dry and wet Age-related Macular Degeneration (AMD) and other chronic diseases involving the alternative complement system, has raised $37 million in start up financing. The company plans to develop...

  • Optherion's AMD Drug Nabs $37M Series A.  // Bioworld Week;10/15/2007, Vol. 15 Issue 42, p3 

    The article reports that Optherion Inc. in Connecticut has raised $37 million in a Series A round to further preclinical research with a new approach for the diagnosis and treatment of age-related macular degeneration (AMD). Optherion focuses on genetic mutations in Complement Factor H, which...

  • Earnings Roundup.  // BioWorld Today;7/30/2008, Vol. 19 Issue 147, p3 

    The article reports on the decrease in the total revenue of QLT Inc. for the quarter ending June 30, 2008. The decrease was attributed to the drop in worldwide sales of age-related macular degeneration treatment Visudyne. The company reported a loss per share of 10 cents and ended the...

  • Financings Roundup.  // BioWorld Today;4/10/2008, Vol. 19 Issue 70, p6 

    The article reports on a $12 million round of financing completed by Potentia Pharmaceuticals Inc. of Louisville, Kentucky. The fund will be used to complete the company's Phase I study of POT-4, a potential treatment for age-related macular degeneration, and move it into Phase II. The drug is a...

  • TargeGen Advances Topical AMD Program With $40M Series D. Boggs, Jennifer // BioWorld Today;7/16/2007, Vol. 18 Issue 136, p1 

    This article reports on the funding deal closed by TargeGen Inc. for the Phase II trial of its eye drop for treating age-related macular degeneration (AMD) and other back-of-the-eye diseases. Information is presented on the total amount of money raised by the firm since its founding in 2002. The...

  • Ophthotech Gets $30M Series B for Trials of Lucentis Add-Ons. Morrison, Trista // BioWorld Today;12/15/2009, Vol. 20 Issue 240, p1 

    The article reports on the 30 million U.S. dollar Series B financing secured by Ophtotech Corp. The financing round is designed to support the clinical trials of the company's age-related macular degeneration (AMD) drugs. Samir Patel, president and chief executive officer (CEO) of Ophthotech,...

  • PanOptica Raises $30M Series A for AMD Eye Drop Candidate. Wall, Tom // BioWorld Today;1/4/2011, Vol. 22 Issue 2, p1 

    The article reports on the Series A financing raised by Mount Arlington, New Jersey-based PanOptica Inc. for its eye drop treatment for neovascular age-related macular degeneration (AMD). A brief background on the competition in the wet AMD market is provided. The financing round coincided with...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics